Home
About
Overview
Sharing Data
ORCID
Help
History (3)
A bioactive injectable bulking material; a potential therapeutic approach for stress urinary incontinence.
Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC).
Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A bioactive injectable bulking material; a potential therapeutic approach for stress urinary incontinence.
A bioactive injectable bulking material; a potential therapeutic approach for stress urinary incontinence. Biomaterials. 2019 06; 206:41-48.
View in:
PubMed
subject areas
Animals
Biocompatible Materials
Female
Fibrin
Humans
Immunohistochemistry
Mice
Myocytes, Smooth Muscle
Rabbits
Urinary Incontinence, Stress
Urinary Tract
authors with profiles
Jeffrey Hubbell